Hematology and Oncology Study Experience

  • Acute myelogenous leukemia (AML)
  • Anal
  • Anemia
  • Anti-thrombin deficiency
  • Bladder
  • Brain
  • Breast
  • Cervical
  • Chronic lymphocytic leukemia (CLL)
  • Chronic myelogenous leukemia (CML)
  • Colorectal
  • Cutaneous T-cell lymphoma
  • Gastric
  • Glioblastoma multiforme (GBM)
  • Thrombocythemia
  • Thyroid
  • Uterus
  • Hemophilia
  • Hepatic
  • Leptomeningeal carcinoma
  • Melanoma
  • Mucositis
  • Multiple myeloma deficiency
  • Myelodysplastic syndromes
  • Myeloproliferative disease
  • Non-Hodgkins lymphoma
  • Non-small cell lung cancer (NSCLC)
  • Ovary
  • Pancreas
  • Post-herpetic neuralgia (PHN)
  • Prostate
  • Renal cell
  • Squamous cell carcinoma (SCCHN)
  • Skin

Therapeutic Experience

  • Antiangiogenic agents
  • Antisense therapy
  • Biological response modifier (e.g., cytokines, MAb)
  • Chemosensitizers
  • Cytotoxics (systemic and topical)
  • Gene therapy
  • Hematopoeitic growth factors
  • Hormonal therapy
  • Radioisotopes
  • Radiotherapy
  • Regional administration
  • Targeted therapy

Hematology/Oncology Study Experience

Awarded Phase Experience (last five years)

Phase Number of Studies
I 115
II 159
III 134
IV 21
Other 31

 

Study Site Experience

Location Number of Studies
Global studies 87
North America 261
Latin America 49
Asia, including India 47
South Africa 19
Middle East 23
Eastern and Western Europe, including Russia 46
Central Europe 98

 

Biomarker Experience

PPD biomarker technology and research capabilities can be utilized to add value along the entire drug discovery and development process, including:

  • Target discovery and clinical validation of candidate targets
  • Increased understanding of drug effects
  • Improved in vivo models of disease
  • More rapid determination of efficacy, safety and optimal dosing regimens
  • Patient stratification by disease sub-type and response to therapy

Our research yields biomarkers and information that enable more efficient discovery and development of new hematology and oncology therapeutics, as well as development of diagnostic tests for early disease detection. These biomarkers can also accurately determine disease sub-types and predict and monitor responses to therapy.